Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity
Biophytis confirms the launch of the Phase 2 OBA clinical study in obesity, expected to begin as early as possible in 2025.
Following the recent €2.6 million capital increase announced on March 26, 2025, and promising preclinical results presented at the 15th International Conference on Frailty and Sarcopenia in Toulouse, Biophytis will continue the clinical development of BIO101 in obesity. The goal is to evaluate the efficacy and safety of BIO101 in reducing muscle strength loss caused by GLP-1 agonists in patients with obesity.
As a reminder, Biophytis received Investigational New Drug (IND) clearance from the FDA in July 2024, marking a major milestone for the OBA program, which benefits from the expertise of Professor Marc-André Cornier, a world-renowned expert in the field of obesity.
Stanislas Veillet, CEO of Biophytis, stated: “The company’s priority is now to find a pharmaceutical partner to co-develop BIO101 in obesity. This partner will support us in the clinical and regulatory development of our drug candidate through to marketing authorization and will lead the product launch in North America.”